Cell Viability Assays Market (2026 - 2033)

Cell Viability Assays Market Summary

The global cell viability assays market was valued at USD 1.9 billion in 2025 and is projected to grow from USD 2.0 billion in 2026 to USD 4.2 billion in 2033, at a CAGR of 10.9% from 2026 to 2033. North America cell viability assays market held the largest revenue share of over 35.0% in 2025. Rising pharmaceutical and biotechnology R&D activities, particularly in oncology and biologics development, are fueling demand for cell viability assays. 

These assays play a critical role in evaluating drug efficacy and toxicity, making them essential tools in modern drug development and cell-based research workflows. The increasing funding for cell-based research is creating more growth opportunities in the cell viability assays market. For instance, in November 2025, Aspen Neuroscience, Inc., a biotechnology company focused on autologous regenerative therapies, closed a USD 115 million Series C financing round to advance its lead program, ANPD001, for moderate-to-advanced Parkinson’s disease. Similarly, TTP Cellular Origins secured USD 40 million in Series A funding to accelerate the development of scalable cell-therapy manufacturing technologies. These investments show a growing interest in cell therapy innovation, which relies heavily on cell viability assays for process improvement, quality control, and effectiveness checks.

In addition, key market players are introducing advanced analytical technologies to meet the growing demand from pharmaceutical, biopharmaceutical, and research organizations. In May 2025, Becton, Dickinson and Company (BD) launched a next-generation cell analyzer that combines spectral analysis and real-time cell imaging capabilities. This allows for deeper insights into cellular behavior with greater accuracy and efficiency.

Furthermore, government and institutional funding for stem cell research is boosting market growth. In January 2025, the California Institute for Regenerative Medicine (CIRM) awarded nearly USD 100 million to support regenerative medicine projects at various stages. Similarly, in October 2025, the Maryland Stem Cell Research Commission provided USD 4.7 million in grants to promote stem cell-based therapeutic development. Together, these initiatives are expected to significantly increase the use of cell viability assays in life sciences research and clinical applications.

Market Dynamics

Analyst Perspective

The cell viability assays market is growing due to increased research in drug discovery, cancer biology, and regenerative medicine. Pharmaceutical and biotechnology companies, along with academic and research institutions, are turning to cell viability testing to assess drug efficacy, cytotoxicity, and cellular responses. The rise in chronic diseases and cancer is also increasing the demand for advanced cell-based assays in preclinical studies. Technological advances such as high-throughput screening, fluorescence-based detection, and automated imaging systems are improving the accuracy and efficiency of laboratory workflows. Market players have the chance to develop sensitive, automated, and cost-effective assay platforms that speed up drug screening, enhance reproducibility, and integrate easily with digital lab systems.

Product Insights

The consumables segment dominated the market in 2025 and captured over 60.0% share. The segment is also anticipated to expand at the fastest rate during the forecast period. This can be attributed to the utility of consumables in various pharmaceutical and biopharmaceutical, diagnostic, and stem cell research applications. In addition, several players in the market are offering a wide range of cell viability assay reagents that are non-toxic and ready to use and offer instant high-quality results. Luminometric assays held a dominant share in 2025 and are anticipated to witness the fastest growth in the projected timeframe due to their simple protocols, uncomplicated equipment requirement, robustness, and superior sensitivity. Fluorometric assays accounted for the second-largest share in 2025 due to their advantages over colorimetric and dye exclusion assays since they are more sensitive. These qualities altogether enable easy scalability and adaptability from bench research to high throughput applications. Such features of cell viability assay are boosting the consumables segment growth.

The instruments segment is expected to witness significant growth during the forecast period. The need for automation, precision, and high-throughput analysis is encouraging the use of advanced instruments such as spectrophotometer, microscopy, cell imaging and analysis system, flow cytometry and high-content screening systems. These instruments allow for accurate measurement of cell health, metabolic activity, and treatment response. Ongoing technology improvements, including real-time imaging and multi-parameter analysis features, are speeding up instrument use in research and clinical settings.

Application Insights

The stem cell research segment held the largest share of over 41.0% in 2025 and is anticipated to register the fastest CAGR during the forecast period. Stem cell therapy is quickly becoming a promising area of biomedical research. This growth has increased the need for cell viability tests to evaluate cell growth, differentiation, and survival. The rising interest in regenerative medicine and complex 3D cell culture models is driving the creation of new analytical tools to support effective research workflows. For instance, in July 2025, Sartorius launched the Incucyte CX3 Live-Cell Analysis System. This system improves 3D cell culture analysis with confocal fluorescence imaging, flexible throughput options, and integrated software. It aims to simplify laboratory workflows and enhance real-time decision-making in drug discovery and development. These technological advancements are increasing the use of cell viability assays in stem cell therapy research. They help researchers better assess cellular behavior and accelerate progress in regenerative medicine applications.

The drug discovery and development segment held the second-largest share in 2025. Cell viability assays play a vital role in various stages of drug discovery and development due to their versatility, flexibility, and adaptability. Cell viability assays are fundamentally used for screening the response of the cells against a chemical compound or a drug during the drug discovery and development process. Furthermore, they are used to estimate the cellular variations related to cell death, such as modifications in protein expression and loss of membrane integrity in enzymatic activity upon exposure to a test compound. Such applications of cell viability assay in drug discovery and development are driving the segment.

End-user Insights

The biopharmaceutical and pharmaceutical companies segment captured the largest revenue share, at over 31.5%, in 2025. This growth is due to the widespread use of cell viability assays to evaluate the biological effects of therapeutic compounds on living cells. These assays are commonly used in oncology research to test drug effectiveness against tumor cells and to assess cytotoxicity and overall safety during both the early and late stages of drug development. Their ability to provide important insights into cellular responses makes them a vital tool throughout various stages of the drug development process. In addition, strong investments in research and development for biologics, targeted therapies, and new treatment methods are boosting their use in this segment.

CROs and CMOs are expected to grow at the fastest rate of xx% over the forecast period. Pharmaceutical companies are entering into collaborations with CROs and CMOs for numerous reasons. These collaborations have the potential to improve process efficiency, cut costs, and decrease time to market. Contract research organizations and contract manufacturing organizations are increasingly using cell viability assays to enhance outsourced drug development and manufacturing services. The trend of outsourcing in pharmaceutical research and development, along with the cost and scalability benefits offered by CROs and CMOs, is driving the demand for standardized, high-throughput assay solutions that ensure consistent and reliable results across various client projects.

Regional Insights

North America dominated the market, accounting for over 35.0% of revenue in 2025. This major share can be attributed to the rise in investment initiatives by the government, the increasing incidence of chronic diseases such as cancer, and the presence of high-quality infrastructure for clinical and laboratory research in North America. For instance, according to the American Cancer Society, approximately 2,041,910 new cancer cases were recorded in the U.S. in 2025, with nearly 618,120 deaths. Thus, the rising prevalence of chronic and infectious diseases and the increasing focus on cell-based therapeutics are expanding the growth prospects of the market.

Asia Pacific Cell Viability Assays Market Trends

Asia Pacific is expected to witness the fastest growth over the forecast period due to rising demand for novel therapeutics in the region. Furthermore, this growth stems from the quick expansion of the pharmaceutical and biotechnology industries, more investment in life sciences research, and a growing use of new drug discovery technologies. Increased government funding for stem cell research and regenerative medicine, especially in countries including China, India, Japan, and South Korea, is also driving demand. In addition, a rising number of contract research organizations (CROs) and budget-friendly R&D capabilities are also helping the regional market grow.

Key Cell Viability Assays Company Insights

Major players in the market are executing numerous strategies including novel product launches, partnerships, collaborations, mergers and acquisitions, and geographical expansion to expand their market presence.

• In March 2026, Elabscience launched its next-generation Cell Viability Chemiluminescence Assay Kit. This new ATP-based luminescence solution provides a reliable way to measure cell viability. The assay works on the idea that ATP, a vital energy molecule in oxidative phosphorylation, indicates cellular metabolic activity and viability levels. The product has a wide detection range of 500 to 50,000 cells, making it ideal for both high- and low-density samples, including rare or limited cell populations. 

• In March 2025, Sphere Bio, a provider of advanced picodroplet-based microfluidics solutions launched the Viability Assay Kit and Cyto-Cellect Human IgG Kappa. This is the first multiplexed assay designed for the company’s newly introduced Cyto-Mine Chroma platform, further expanding its capabilities in high-throughput single-cell screening and analysis.

Key Cell Viability Assays Companies

The following key companies have been profiled for this study on the cell viability assays market.

• Thermo Fisher Scientific, Inc.

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• Merck KGaA

• Waters Corporation

• Revvity, Inc.

• Promega Corporation

• Biotium

• Creative Bioarray

• Abcam plc

• Charles River Laboratories

Cell Viability Assays Market Report Scope

Global Cell Viability Assays Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global cell viability assays market report based on product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Consumables

    • Reagents And Assay Kits, By Type

      • Dye Exclusion Assays

      • Colorimetric Assays

      • Fluorometric Assays

      • Luminometric Assays

    • Microplates

  • Instruments

    • Spectrophotometer

    • Microscopy

    • Cell Imaging And Analysis System

    • Flow Cytometry

    • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Drug Discovery And Development

  • Stem Cell Research

  • Diagnostics

• End-user Outlook (Revenue, USD Million, 2021 - 2033)

  • Biopharmaceutical & Pharmaceutical Companies

  • CROs & CMOs

  • Academic & Research Institutes

  • Diagnostic Labs

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait